ESTRO 2024 - Abstract Book

S1586

Clinical - Lung

ESTRO 2024

Results:

Twenty-nine patients were enrolled and 20 were analyzed in this report for acute and late toxicity. The median follow-up was 27,5 months (range: 4 – 51 months). The vast majority of patients presented epithelioid histology and past asbestos exposure (75%). Thirty percent of patients underwent radiotherapy after biopsy, 70% after P/D. Standard of care Platinum-pemetrexed based chemotherapy was administered for all 20 patients with an average number of cycles of 4 (range 3-6 cycles). All patients have been subjected to respiratory function tests pre radiotherapy and then during follow up every 6 months. The total of 20 patients was considered for the evaluation of acute and late toxicity. One case of G3 lung toxicity was reported, which was bilateral pneumonitis occurred 2 years after treatment probably due to a superinfection. Acute and late toxicity data about pneumonitis, dyspnea, cough, fever,fatigue, pleural effusion, pericardial effusion, chest pain, dysphagia, haemophtoe, skin disorders, mastitis are reported with the exclusion of G3. Median Time to Progression reached 18.2 months while one- and two-year Overall Survival rates were 84.4% (95% CI: 59.1-94.7) and 58.1% (95% CI: 33.4-76.4), respectively.

Conclusion:

Our preliminary data about adjuvant radiotherapy treatment in MPM patients after pleurectomy/decortication using accelerated hypofractionated schedule is safe and feasible, without a high grade of lung toxicity. Patients demonstrated high grade of compliance due to short time of the treatment. Survival rates and Time to Progression are encouraging, particularly in patients who underwent adequate surgery after chemotherapy without residual disease. The trial is ongoing, this is an interim analysis of the first preliminary data, we have to wait its closure for definitive data.

Keywords: mesothelioma, hypofractionation, pneumonitis

References:

1.Parisi E., Romeo A., Sarnelli A., Ghigi G., Bellia S.R., Neri E., Micheletti S., Dipalma B., Arpa D., Furini G., et al. High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment. Cancer Radiother. 2017;21:766 – 773 2.de Perrot M., Feld R., Leighl N.B., Hope A., Waddell T.K., Keshavjee S., Cho B.C. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2016;151:468 – 473

178

Proffered Paper

Multimodality treatment in synchronous oligometastatic NSCLC: final analysis of the ETOP CHESS trial

Matthias Guckenberger 1 , Isabelle Opitz 2 , Maria Tereza Dellaporta 3 , Alessandra Curioni-Fontecedro 4,5 , Thomas Frauenfelder 6 , Ferdinando Cerciello 7,5 , Ivana Sullivan 8,9 , Lizza Hendriks 10 , Miriam Dorta 11,9 , Ana Callejo 12,9 , Joachim